van Duijn-de Vreugd

May 6, 2024 | link.springer.com | van der Meer |van Rijswijk |van Erkel |van Duijn-de Vreugd

AbstractPercutaneous hepatic perfusion with melphalan (M-PHP) is a minimally invasive therapy with proven efficacy in patients with uveal melanoma (UM) liver metastases. M-PHP is associated with a short hospital admission time and limited systemic side effects. In this study, we assessed quality of life (QoL) in UM patients treated with M-PHP. A prospective, single-center study including 24 patients treated with M-PHP for UM metastases to the liver.